Duloxetine hepatotoxicity: A case-series from the drug-induced liver injury network

Raj Vuppalanchi, P. H. Hayashi, Naga Chalasani, R. J. Fontana, H. Bonkovsky, Romil Saxena, D. Kleiner, J. H. Hoofnagle

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background Case reports suggest that duloxetine hepatotoxicity may arise, but risk factors, presenting features and clinical course are not well-described. Aim To describe the presenting features and outcomes of seven well-characterized patients with suspected duloxetine hepatotoxicity. Methods Patients enrolled in the Drug-Induced Liver Injury Network Prospective Study underwent an extensive laboratory and clinical evaluation to exclude competing aetiologies of liver injury as well as a standardized assessment for causality and disease severity. Results Between 1 / 2006 and 9 / 2009, six of the seven cases of DILI attributed to duloxetine were assessed as definite or very likely. Median patient age was 49 years, six (86%) were women and the median latency from drug initiation to DILI onset was 50 days. Six patients developed jaundice and the median peak alanine aminotransferase in the five patients with acute hepatocellular injury was 1633 IU/ L. Ascites developed in one patient and acute renal dysfunction in two others (29%). All patients recovered without liver transplantation even though three had pre-existing chronic liver disease. Liver histology in four cases demonstrated varying patterns of liver injury. Conclusions Duloxetine hepatotoxicity developed within 2 months of drug intake and led to clinically significant liver injury. A spectrum of laboratory, histological and extra-hepatic features were noted at presentation.

Original languageEnglish
Pages (from-to)1174-1183
Number of pages10
JournalAlimentary Pharmacology and Therapeutics
Volume32
Issue number9
DOIs
StatePublished - Nov 2010

Fingerprint

Chemical and Drug Induced Liver Injury
Liver
Wounds and Injuries
Jaundice
Duloxetine Hydrochloride
Alanine Transaminase
Ascites
Causality
Pharmaceutical Preparations
Liver Transplantation
Liver Diseases
Histology
Chronic Disease
Prospective Studies
Kidney

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Duloxetine hepatotoxicity : A case-series from the drug-induced liver injury network. / Vuppalanchi, Raj; Hayashi, P. H.; Chalasani, Naga; Fontana, R. J.; Bonkovsky, H.; Saxena, Romil; Kleiner, D.; Hoofnagle, J. H.

In: Alimentary Pharmacology and Therapeutics, Vol. 32, No. 9, 11.2010, p. 1174-1183.

Research output: Contribution to journalArticle

Vuppalanchi, Raj ; Hayashi, P. H. ; Chalasani, Naga ; Fontana, R. J. ; Bonkovsky, H. ; Saxena, Romil ; Kleiner, D. ; Hoofnagle, J. H. / Duloxetine hepatotoxicity : A case-series from the drug-induced liver injury network. In: Alimentary Pharmacology and Therapeutics. 2010 ; Vol. 32, No. 9. pp. 1174-1183.
@article{338bf0bea6cf4fc2bd4c941a4f9157b2,
title = "Duloxetine hepatotoxicity: A case-series from the drug-induced liver injury network",
abstract = "Background Case reports suggest that duloxetine hepatotoxicity may arise, but risk factors, presenting features and clinical course are not well-described. Aim To describe the presenting features and outcomes of seven well-characterized patients with suspected duloxetine hepatotoxicity. Methods Patients enrolled in the Drug-Induced Liver Injury Network Prospective Study underwent an extensive laboratory and clinical evaluation to exclude competing aetiologies of liver injury as well as a standardized assessment for causality and disease severity. Results Between 1 / 2006 and 9 / 2009, six of the seven cases of DILI attributed to duloxetine were assessed as definite or very likely. Median patient age was 49 years, six (86{\%}) were women and the median latency from drug initiation to DILI onset was 50 days. Six patients developed jaundice and the median peak alanine aminotransferase in the five patients with acute hepatocellular injury was 1633 IU/ L. Ascites developed in one patient and acute renal dysfunction in two others (29{\%}). All patients recovered without liver transplantation even though three had pre-existing chronic liver disease. Liver histology in four cases demonstrated varying patterns of liver injury. Conclusions Duloxetine hepatotoxicity developed within 2 months of drug intake and led to clinically significant liver injury. A spectrum of laboratory, histological and extra-hepatic features were noted at presentation.",
author = "Raj Vuppalanchi and Hayashi, {P. H.} and Naga Chalasani and Fontana, {R. J.} and H. Bonkovsky and Romil Saxena and D. Kleiner and Hoofnagle, {J. H.}",
year = "2010",
month = "11",
doi = "10.1111/j.1365-2036.2010.04449.x",
language = "English",
volume = "32",
pages = "1174--1183",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Duloxetine hepatotoxicity

T2 - A case-series from the drug-induced liver injury network

AU - Vuppalanchi, Raj

AU - Hayashi, P. H.

AU - Chalasani, Naga

AU - Fontana, R. J.

AU - Bonkovsky, H.

AU - Saxena, Romil

AU - Kleiner, D.

AU - Hoofnagle, J. H.

PY - 2010/11

Y1 - 2010/11

N2 - Background Case reports suggest that duloxetine hepatotoxicity may arise, but risk factors, presenting features and clinical course are not well-described. Aim To describe the presenting features and outcomes of seven well-characterized patients with suspected duloxetine hepatotoxicity. Methods Patients enrolled in the Drug-Induced Liver Injury Network Prospective Study underwent an extensive laboratory and clinical evaluation to exclude competing aetiologies of liver injury as well as a standardized assessment for causality and disease severity. Results Between 1 / 2006 and 9 / 2009, six of the seven cases of DILI attributed to duloxetine were assessed as definite or very likely. Median patient age was 49 years, six (86%) were women and the median latency from drug initiation to DILI onset was 50 days. Six patients developed jaundice and the median peak alanine aminotransferase in the five patients with acute hepatocellular injury was 1633 IU/ L. Ascites developed in one patient and acute renal dysfunction in two others (29%). All patients recovered without liver transplantation even though three had pre-existing chronic liver disease. Liver histology in four cases demonstrated varying patterns of liver injury. Conclusions Duloxetine hepatotoxicity developed within 2 months of drug intake and led to clinically significant liver injury. A spectrum of laboratory, histological and extra-hepatic features were noted at presentation.

AB - Background Case reports suggest that duloxetine hepatotoxicity may arise, but risk factors, presenting features and clinical course are not well-described. Aim To describe the presenting features and outcomes of seven well-characterized patients with suspected duloxetine hepatotoxicity. Methods Patients enrolled in the Drug-Induced Liver Injury Network Prospective Study underwent an extensive laboratory and clinical evaluation to exclude competing aetiologies of liver injury as well as a standardized assessment for causality and disease severity. Results Between 1 / 2006 and 9 / 2009, six of the seven cases of DILI attributed to duloxetine were assessed as definite or very likely. Median patient age was 49 years, six (86%) were women and the median latency from drug initiation to DILI onset was 50 days. Six patients developed jaundice and the median peak alanine aminotransferase in the five patients with acute hepatocellular injury was 1633 IU/ L. Ascites developed in one patient and acute renal dysfunction in two others (29%). All patients recovered without liver transplantation even though three had pre-existing chronic liver disease. Liver histology in four cases demonstrated varying patterns of liver injury. Conclusions Duloxetine hepatotoxicity developed within 2 months of drug intake and led to clinically significant liver injury. A spectrum of laboratory, histological and extra-hepatic features were noted at presentation.

UR - http://www.scopus.com/inward/record.url?scp=78649473610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649473610&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2010.04449.x

DO - 10.1111/j.1365-2036.2010.04449.x

M3 - Article

C2 - 20815829

AN - SCOPUS:78649473610

VL - 32

SP - 1174

EP - 1183

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 9

ER -